-
1
Ivonescimab, a PD-1/VEGF bispecific antibody, improved overall survival in advanced squamous NSCLC compared to PD-1 plus chemotherapy.
-
2
The phase 3 HARMONi-6 trial showed a 34% reduced risk of death with ivonescimab, achieving median overall survival of 27.9 months.
-
3
Amgen's Imdylltra received EU approval as a monotherapy for extensive-stage small cell lung cancer, showing a 40% reduced risk of death.
-
4
Renaissance Pharma's anti-GD2 mAb, Daretabart, targets high-risk neuroblastoma and has shown promising survival rates in pediatric patients.
-
5
Pfizer and Innovent Biologics entered a $10.5 billion oncology collaboration to develop 12 early-stage programs, retaining rights in Greater China.
